Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possi… (NCT07746882) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy
680 participantsStarted 2026-08-15
Plain-language summary
To screen ischemic stroke patients likely to benefit from anticoagulation and compare the effectiveness and safety of anticoagulation versus antiplatelet therapy in preventing recurrent ischemic stroke within 3 months.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Cortical or multi-territorial infarct
. Recurrent stroke or stroke on antiplatelet therapy
. Left atrial diameter \>40 mm
. Left ventricular dysfunction (EF 30-40% or regional wall motion abnormality)
. Atrial premature beats \>1500/24h
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is comparing different anti-thrombotic regimens for people who might benefit from anticoagulation after an ischemic stroke — does my specific stroke type or cause make me a potential candidate worth discussing with you?
2Since the trial is Phase 3, what does that mean for what's already known about the safety and effectiveness of the anticoagulation approaches being tested, compared to whatever standard treatment you'd normally recommend for me?
3The trial isn't recruiting yet — if it opens in the future and you think it could be a good fit for me, what would I need to do in the meantime, and would starting standard treatment now affect my eligibility later?
4The main outcome being measured is whether ischemic stroke recurs within 3 months — how does that short follow-up period factor into your thinking about whether a trial like this offers enough information to guide my longer-term treatment decisions?
5Are there already approved anticoagulation options that might address my situation right now, and how would you weigh those against waiting to see if this trial becomes available and enrolling in it?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
3-month ischemic stroke recurrence
Timeframe: 90 ± 7 days
Trial details
NCT IDNCT07746882
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine